TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00715208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT00052338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03309618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05322486

Intervention type: PROCEDURE
Intervention: surgery of the primary tumour
Description: Surgical resection of the colon tumour, R0. No surgical intervention on metastasis.

Intervention type: DRUG
Intervention: chemotherapy
Description: Chemotherapy with or without biological drugs.
Study: NCT02121080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2222(SAR438584)
Study: NCT05322486

Intervention type: DRUG
Intervention: chemotherapy
Description: Chemotherapy with or without biological drugs.
Study: NCT01294046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation of SPG for Migraine
Description: Deep Brain Stimulation of SPG for Migraine
Study: NCT03984929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conexion Localized
Description: The localized version of Conexion is an online health information resource on diabetes and depression tailored for the target community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conexion Generic
Description: The generic version of Conexion is an online health information resource on diabetes and depression.
Study: NCT01408693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-gluteal approach, CLAS
Description: Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior minimal invasive approach, AMIS
Description: Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
Study: NCT02211027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Semi-allogenic human fibroblast (MRC-5) transfected with DNA
Description: Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site.
Study: NCT03003117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention Program
Description: The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), and lifestyle behaviors, consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets, kitchen utensils and cooking devices are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula, baby and family food vouchers from 6 to 24 m (component 3).~One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Usual Care
Description: Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
Study: NCT02556749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Juice Beverage
Description: 16 ounces of 54% cranberry juice cocktail

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Color, calorie, and taste matched beverage without cranberry bioactives
Study: NCT02121080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2222(SAR438584)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2222(SAR438584)
Study: NCT04454606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fit test
Description: Bitrex Fit Test The Bitrex test uses a person's ability to test a bitter solution to determine whether a respirator fits properly\[11\]. Each subject was given a taste-threshold screening test prior to each fit test to ensure that he or she could taste. This process was done without subject wearing a respirator. After passing the sensitivity test, the subject will process to 7 steps of fit test as following~* Breathe normally~* Breathe deeply~* Head side to side~* Head up and down~* Bent over wrist, jogging~* Talking~* Breath normally Each step took 60 seconds and the Bitrex solution was refilled into the hood every 30 seconds with half dosage of the amount of the previously test. We asked the participant if he / she could taste the solution during each steps of the test . The test was considered a failure, otherwise, a pass.
Study: NCT02121080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT04454606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtration Test
Description: Respirator Performance~The real time respirator performance test method was developed using MT-05U machine (SIBATA model, Saitama, Japan), which measure particle concentrations of diameter 0.03 - 0.06 µm using and particle generator laser beam scattering particle counter that measure particles outside and inside the mask. The ratio between these two values reflected % leak as following:~* leak=((Paticle inside the filter))/((Paticle inside the filter)) x 100 And calculate % filter performance = 100 - % leak We tested at the airflow rate of 40L/min which is 3-4 times higher than normal physiology, assuming that there should be no leakage through the filter. We tested 2 types of filter is CareStar and SafeStar that was incorporated with the silicone mask. CareStar is limited for 24 hour usage and SafeStar is for 72 hour duration.~Study protocol
Study: NCT02121080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT04213248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Mesenchymal Stem Cells derived Exosomes
Description: Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
Study: NCT00161343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Improvement Project for Teens on HIV Prevention
Description: Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Improvement Project for Teens on HIV Prevention
Description: Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
Study: NCT02659891

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVIg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01151904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution
Description: COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost
Description: Latanoprost administered in the affected eye(s) as prescribed by physician.
Study: NCT03279562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Educational and behaviorally oriented drug counseling
Study: NCT04658199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0107 (bepranemab)
Description: UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous
Study: NCT00276523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery
Description: Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Study: NCT03616301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavamox
Description: Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin®
Description: Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia
Study: NCT02984605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional meal replacement
Description: 1 times a day with bags of nutritional meal replacement + individualized exercise prescription
Study: NCT01472718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary thrombectomy
Description: coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard primary PCI (with stenting, as required)
Description: standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
Study: NCT01794286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider bulletins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trigger alerts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger alerts
Study: NCT03629496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arts-based intervention
Description: 6x1 hourly facilitated art sessions during haemodialysis. Participants will be provided with an option of visual art or creative writing, the artistic materials used will include graphite pencils, colouring pencils, water colour paints and graphic pens. Participants will be provided with their own art supplies for infection control purposes. During each session participants will be allowed to self-select a subject matter or be provided with binary prompts to facilitate decision making. Participants will also have an option of displaying completed work in the reception area of the unit during their haemodialysis sessions.
Study: NCT01901250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylitol gummy bears
Description: The children receive xylitol gummy bears 3 times/day within the supervised school environment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar free fiber gummy bears
Description: The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral health education
Description: Oral health education, toothbrush, and fluoride toothpaste

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral health education
Description: Oral health education, toothbrush, and fluoride toothpaste
Study: NCT04322851

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Lung ultrasound performed at the time of extubation to evaluate B-line in patients with mechanical ventilation due to acute decompensated heart failure

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Lung ultrasound performed at the time of extubation to evaluate B-line in patients with mechanical ventilation due to acute decompensated heart failure
Study: NCT03536871

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi-nutrient supplement
Description: Compare the effects of a multi-nutrient supplement following a healthy lifestyles program in healthy young men and women, healthy older men, and sarcopenic older men.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: We will evaluate the effect of 12 weeks of combined endurance and resistance home-based exercise in younger and older adults.
Study: NCT03098784

Intervention type: OTHER
Intervention: Exposure to aircraft exhaust
Description: The exposed group is made up of Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports. These people are subject to direct exposure to exhaust from aircraft engines.

Intervention type: OTHER
Intervention: Non exposure to aircraft exhaust
Description: The non-exposed group is made up of Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports. These people are not subject to direct exposure to exhaust from aircraft engines.
Study: NCT01545856

Intervention type: DRUG
Intervention: levodopa
Description: levodopa use
Study: NCT00505440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone case management and motivational interviewing
Description: 'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care with mailed screening results
Study: NCT03456752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8mg intravenously prior to induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 1.6ml intravenously prior to induction of anesthesia
Study: NCT03709173

Intervention type: BEHAVIORAL
Intervention: FuRST 2.0
Description: Round 2 of cognitive pre-testing for a new functional rating scale

Intervention type: BEHAVIORAL
Intervention: FuRST 2.0
Description: Round 2 of cognitive pre-testing for a new functional rating scale
Study: NCT01901250

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride varnish
Description: The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
Study: NCT00273104

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle intervention
Description: Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
Study: NCT00317109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™- HepB
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™- HepB
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
Study: NCT01901250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
Study: NCT00317109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix™
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
Study: NCT01901250

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dental sealant
Description: The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental sealant
Description: The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
Study: NCT00511368

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Study: NCT00317109

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax™ ACW
Description: One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACW
Description: One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
Study: NCT03916211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs treatment
Description: intramuscular injection of adipose stem cells treat diabetic foot
Study: NCT03991689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solution-focused group therapy
Description: Participants began a 90-minute solution-focused pain management group, which lasted for six weeks, and after the group ended, the questionnaire post-test was carried out, and a total of 26 participants thus completed their group journey. The group effect was evaluated by the difference between the scores of the questionnaires before and after the group.
Study: NCT03177421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problematic bedtime media use counseling
Description: Participants will be screened for bedtime media use and sleep problems, and the clinical decision support system will recommend counseling on the respective problems identified on screening.

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep problem counseling
Description: Participants will be screened for sleep problems, and the clinical decision support system will recommend counseling if problems are identified.
Study: NCT00678873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Cholecystectomy
Description: A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
Study: NCT00985335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neem Based External Application Cream
Description: Apply externally 3-4 times per day
Study: NCT00511368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevirimat
Study: NCT04274946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Description: Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Description: Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.
Study: NCT04634500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin Tablet